Insider Selling: Capricor Therapeutics (NASDAQ:CAPR) Director Sells 7,529 Shares of Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Director Karimah Es Sabar sold 7,529 shares of the stock in a transaction on Thursday, April 2nd. The shares were sold at an average price of $32.00, for a total value of $240,928.00. Following the completion of the transaction, the director directly owned 7,529 shares in the company, valued at approximately $240,928. This represents a 50.00% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Karimah Es Sabar also recently made the following trade(s):

• On Wednesday, April 1st, Karimah Es Sabar sold 53,735 shares of Capricor Therapeutics stock. The stock was sold at an average price of $31.03, for a total value of $1,667,397.05.
• On Tuesday, March 31st, Karimah Es Sabar sold 61,265 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.17, for a total value of $1,848,365.05.

Capricor Therapeutics Stock Performance

Shares of Capricor Therapeutics stock remained flat at $32.11 during trading on Friday. The stock had a trading volume of 1,225,548 shares, compared to its average volume of 1,798,446. The company has a market capitalization of $1.85 billion, a PE ratio of -14.21 and a beta of 0.48. The business has a 50 day simple moving average of $27.20 and a two-hundred day simple moving average of $18.83. Capricor Therapeutics, Inc. has a 12-month low of $4.30 and a 12-month high of $40.37.

Capricor Therapeutics (NASDAQ:CAPR) last released its earnings results on Thursday, March 12th. The biotechnology company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.11). As a group, sell-side analysts expect that Capricor Therapeutics, Inc. will post -1.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on CAPR. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $25.00 to $50.00 and gave the stock a “buy” rating in a report on Thursday, December 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Wall Street Zen downgraded shares of Capricor Therapeutics from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. Piper Sandler restated an “overweight” rating and set a $58.00 price target (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Finally, B. Riley Financial raised their price objective on Capricor Therapeutics from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Friday, March 13th. Nine equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $46.09.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Farther Finance Advisors LLC bought a new stake in Capricor Therapeutics during the 3rd quarter valued at $28,000. Parkside Financial Bank & Trust bought a new stake in Capricor Therapeutics in the 3rd quarter worth $36,000. Russell Investments Group Ltd. increased its position in shares of Capricor Therapeutics by 122.2% in the third quarter. Russell Investments Group Ltd. now owns 5,066 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 2,786 shares during the period. ACT Capital Management LLC purchased a new position in shares of Capricor Therapeutics in the fourth quarter valued at about $43,000. Finally, GoalVest Advisory LLC bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at about $59,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.